Suppr超能文献

布拉氏酵母菌,一种酵母益生菌,通过上调肠道 5-羟色胺转运体和调节肠道微生物群来抑制肠道蠕动。

Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota.

机构信息

Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, China.

Department of Gastroenterology, Tianjin TeDa Hospital, Tianjin, China.

出版信息

Pharmacol Res. 2022 Jul;181:106291. doi: 10.1016/j.phrs.2022.106291. Epub 2022 Jun 8.

Abstract

Saccharomyces boulardii (Sb) is a widely used fungal probiotic in treating various digestive diseases, including irritable bowel syndrome (IBS). However, the specific mechanisms of Sb relieving IBS remain unclear. The abnormal serotonin transporter (SERT) / 5-hydroxytryptamine (5-HT) system could cause disordered gastrointestinal sensation and motility, which closely related to IBS pathogenesis. The aim of this study was to explore the effects and mechanisms of Sb on regulating gut motility. Sb supernatant (SbS) was administered to intestinal epithelial cells and mice. SbS upregulated SERT expression via enhancing heparin-binding epidermal growth factor (HB-EGF) release to activate epidermal growth factor receptor (EGFR). EGFR kinase inhibitor treatment or HB-EGF siRNA transfection in cells blocked SbS upregulating SERT. Consistently, SbS-treated mice presented inhibited gut motility, and EGFR activation and SERT upregulation were found. Moreover, 16 S rDNA sequence presented an evident decrease in Firmicutes / Bacteroidetes ratio in SbS group. In genus level, SbS reduced Escherichia_Shigella, Alistipes, Clostridium XlVa, and Saccharibacteria_genera_incertae_sedis, meanwhile, increased Parasutterella. The abundance of Saccharibacteria_genera_incertae_sedis positively correlated with defecation parameters and intestinal 5-HT content. Fecal microbiota transplantation showed that SbS could modulate gut microbiota to influence gut motility. Interestingly, elimination of gut microbiota with antibiotic cocktail did not entirely block SbS regulating gut motility. Furthermore, SbS administration to IBS-D mice significantly upregulated SERT and inhibited gut motility. In conclusion, SbS could upregulate SERT by EGFR activation, and modulate gut microbiota to inhibit gut motility. This finding would provide more evidence for the application of this yeast probiotic in IBS and other diarrheal disorders.

摘要

布拉氏酵母菌(Sb)是一种广泛应用于治疗各种消化系统疾病的真菌益生菌,包括肠易激综合征(IBS)。然而,Sb 缓解 IBS 的具体机制尚不清楚。异常的血清素转运体(SERT)/5-羟色胺(5-HT)系统可能导致胃肠道感觉和运动紊乱,这与 IBS 的发病机制密切相关。本研究旨在探讨 Sb 调节肠道运动的作用和机制。将 Sb 上清液(SbS)给予肠上皮细胞和小鼠。SbS 通过增强肝素结合表皮生长因子(HB-EGF)的释放来上调 SERT 表达,从而激活表皮生长因子受体(EGFR)。细胞中 EGFR 激酶抑制剂处理或 HB-EGF siRNA 转染阻断了 SbS 上调 SERT。一致地,SbS 处理的小鼠表现出抑制肠道运动,并且发现 EGFR 激活和 SERT 上调。此外,16S rDNA 序列在 SbS 组中呈现出厚壁菌门/拟杆菌门比值的明显降低。在属水平上,SbS 减少了 Escherichia_Shigella、Alistipes、Clostridium XlVa 和 Saccharibacteria_genera_incertae_sedis,同时增加了 Parasutterella。Saccharibacteria_genera_incertae_sedis 的丰度与排便参数和肠道 5-HT 含量呈正相关。粪便微生物群移植表明,SbS 可以调节肠道微生物群来影响肠道运动。有趣的是,用抗生素鸡尾酒消除肠道微生物群并没有完全阻断 SbS 调节肠道运动。此外,SbS 给药给 IBS-D 小鼠可显著上调 SERT 并抑制肠道运动。总之,SbS 可通过 EGFR 激活上调 SERT,并调节肠道微生物群抑制肠道运动。这一发现为该酵母益生菌在 IBS 和其他腹泻性疾病中的应用提供了更多证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验